GC said it has entered into a joint sales partnership with Sanofi-Aventis Korea for the sales and marketing of the latter’s antiplatelet drug, Plavix Tab. 75mg, in Korea.

Under the accord, GC will be in charge of sales and marketing of Plavix Tab. 75mg, focusing on clinics.

Plavix Tab. 75mg is an original antiplatelet product containing clopidogrel, which is prescribed for patients with stroke, myocardial infarction, and peripheral arterial disease.

The main ingredient, clopidogrel, prevents the risk of recurrence in patients with acute coronary syndrome by suppressing the formation of blood clots and preventing the resulting risk.

GC expects synergies with its products in terms of lowering the risk of stroke, myocardial infarction, and peripheral arterial disease, as well as chronic diseases related to dyslipidemia, diabetes, and hypertension.

GC has been strengthening its influence in the combination drug market by sequentially launching the three-drug combo drug Rozetel and the four-drug combo Rozetelpine, which are prescribed for dyslipidemia and hypertension.

"We will continue cooperation such as open innovation and joint sales partnership to provide various treatment options in the management of risk factors for patients with chronic diseases in Korea," a GC official said.